Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant De-Escalated Radiation + Nivolumab for p16+ Oropharynx Cancer
NCT03715946Phase 2Completed
- Start
- Nov 2018
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in oropharyngeal squamous cell carcinoma (OPSCC). Started Nov 2018; status: completed.
02
Drugs
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT03715946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03715946.